SCHEMBL5857767

SCHEMBL5857767

CC1(c2ccccc2)CC(=O)OC(=O)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
BACE1 P56817 2/20 0.40
CFTR P13569 1/20 0.38
GOPC Q9HD26 1/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP2C9 P11712 2/20 0.38
HSD11B1 P28845 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 2/20 0.37
HCAR3 P49019 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
CYP2C19 P33261 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
EGFR P00533 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRK1 P41145 1/20 0.35
OPRL1 P41146 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10017607 0.89 ALDH1A1 (0.40) ALDH1A1CYP2C9KDM4EHPGD
SCHEMBL425311 0.82 MEN1 (0.45) MMP2MMP9BACE1CFTRGOPC
SCHEMBL15116234 0.79 MMP2 (0.38) MMP2MMP9BACE1CFTRGOPC
SCHEMBL13829418 0.79 KDM4E (0.35) ALDH1A1CYP2C9KDM4EHPGD
SCHEMBL9815309 0.78 MEN1 (0.42) MMP2MMP9BACE1CFTRGOPC
SCHEMBL11257113 0.78 ALDH1A1 (0.38) MMP2MMP9BACE1CFTRGOPC
SCHEMBL2608112 0.78 KDM4E (0.34) ALDH1A1KDM4EHPGD
SCHEMBL5858162 0.76 TSHR (0.42) CFTRGOPCMEN1KMT2ACYP1A2
SCHEMBL10768335 0.76 CYP2C9 (0.48) MMP2MMP9BACE1CFTRGOPC
SCHEMBL5678994 0.75 HDAC9 (0.42) MMP2MMP9ALDH1A1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118311802-A Display panel and display device 广州华星光电半导体显示技术有限公司 2024-07-09 CN disclosed
CN-118092026-A Alignment film composition, display panel and manufacturing method thereof TCL华星光电技术有限公司 2024-05-28 CN disclosed
US-7119098-B2 Heteroarylakanoic acids as intergrin receptor antagonists PHARMACIA CORPORATION (US) 2006-10-10 US disclosed
US-6933304-B2 Heteroarylalkanoic acids as integrin receptor antagonists PHARMACIA CORPORATION (US) 2005-08-23 US disclosed
US-20040092497-A1 Heteroarylakanoic acids as intergrin receptor antagonists PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1289983-A2 HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS Pharmacia Corporation (US) 2003-03-12 EP disclosed
US-20020133023-A1 Heteroarylalkanoic acids as integrin receptor antagonists PHARMACIA CORPORATION 2002-09-19 US disclosed
WO-2001096334-A2 HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS PHARMACIA CORPORATION (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020133023-A1 Heteroarylalkanoic acids as integrin receptor antagonists ITGA5, ITGA2B, ITGAV MMP2 1354/4885MMP9 1472/4885BACE1 4226/4885
US-20040092497-A1 Heteroarylakanoic acids as intergrin receptor antagonists ITGA5, ITGB7, ITGA2B MMP2 2429/4885MMP9 1786/4885BACE1 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.